Pillstats
Rx only · Tablet · Oral

Cabergoline

Cabergoline

9 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US12 NDCs
9 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)47579
US makers9 labelers
Packages12
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 7 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$0.423$0.847$1.27$1.69Dec 2025Apr 2026Jul 2026
$1.412
Latest avg · Jul 22, 2026
+4%
Since Dec 17, 2025
9
Active US suppliers
42%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

11K22K32K43K2025 Q12025 Q22025 Q32025 Q42026 Q1
34K
Rx · 2026 Q1
340K
Units dispensed
-7%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it9 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Apr 24, 2012
    RECALLRecall (Class III): CABERGOLINE Tablets, 0.5 mg, RX only, 8 count bottles, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 189…

    Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life — Recalling firm: Teva Pharmaceuticals USA, Inc. — Nationwide